Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/28854
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVajda, Frank J E-
dc.contributor.authorO'Brien, Terence J-
dc.contributor.authorGraham, Janet E-
dc.contributor.authorHitchcock, Alison E-
dc.contributor.authorPerucca, Piero-
dc.contributor.authorLander, Cecilie M-
dc.contributor.authorEadie, Mervyn J-
dc.date2022-02-14-
dc.date.accessioned2022-02-22T04:30:39Z-
dc.date.available2022-02-22T04:30:39Z-
dc.date.issued2022-04-
dc.identifier.citationEpilepsy & Behavior 2022; 129: 108602en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/28854-
dc.description.abstractTo investigate possible factors that influenced whether pregnancy in women with epilepsy resulted in the desirable outcome of a live-born non-malformed infant and a mother whose pregnancy had been seizure free. The desirable outcome, as defined, occurred in 46.3% of unselected pregnancies in the database of the Australian Register of Antiepileptic Drugs in Pregnancy (APR). The only factor investigated that had a statistically significant (P < 0.05) effect, increasing the chance of such a desirable outcome, was freedom from seizures in the pre-pregnancy year. However, anti-seizure medication (ASM) doses, particularly valproate doses, had been reduced prior to 15.6% of the pregnancies, and this may have concealed factors that otherwise may have adversely affected the desirable outcome rate. Analysis of data for monotherapy with the more commonly used ASMs appears to suggest that employing levetiracetam at the outset of antiseizure therapy may offer a better chance of a desirable outcome to future pregnancies than monotherapy with other ASMs, but this finding is not confirmed statistically. In pregnancies where valproate use has already been minimized, seizure control throughout the pre-pregnancy year was associated with the best chance of a desirable outcome, as defined above. In most Australian women starting therapy for epilepsy initiating treatment with levetiracetam monotherapy may offer the best chance of such a desirable outcome to a future pregnancy, yet to be confirmed.en
dc.language.isoeng-
dc.subjectEpilepsyen
dc.subjectFetal malformationen
dc.subjectLevetiracetamen
dc.subjectPregnancyen
dc.subjectSeizure controlen
dc.subjectValproateen
dc.titleAchieving neurologically desirable outcomes to pregnancy in women with epilepsy.en
dc.typeJournal Articleen
dc.identifier.journaltitleEpilepsy & Behavior : E&Ben
dc.identifier.affiliationMedicine (University of Melbourne)en
dc.identifier.affiliationComprehensive Epilepsy Programen
dc.identifier.affiliationDepartment of Neurology, Alfred Health, Melbourne, VIC 3004, Australiaen
dc.identifier.affiliationDepartments of Medicine and Neurosciences, The Royal Melbourne Hospital, The University of Melbourne, Parkville, Victoria 3050, Australiaen
dc.identifier.affiliationDepartment of Neuroscience, Monash University, Melbourne, VIC 3004, Australiaen
dc.identifier.affiliationRoyal Brisbane and Women's Hospital and School of Medicine and Biomedical Science, University of Queensland, Brisbane, QLD 4027, Australiaen
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/35176651/en
dc.identifier.doi10.1016/j.yebeh.2022.108602en
dc.type.contentTexten
dc.identifier.orcid0000-0002-7855-7066en
dc.identifier.pubmedid35176651-
local.name.researcherPerucca, Piero
item.languageiso639-1en-
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.cerifentitytypePublications-
crisitem.author.deptNeurology-
crisitem.author.deptComprehensive Epilepsy Program-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

20
checked on Nov 9, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.